This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teladoc (TDOC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $156.31, moving +0.33% from the previous trading session.
Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $154.82 in the latest trading session, marking a +0.34% move from the prior day.
The Zacks Analyst Blog Highlights: GoodRx Holdings, American Well Corp, Accolade, SOC Telemed and Teladoc
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GoodRx Holdings, American Well Corp, Accolade, SOC Telemed and Teladoc
Booming Telehealth Market Lures More IPOs and M&A Deals
by Sapna Bagaria
To make the most of the booming telehealth industry, players are coming up with IPOs and resorting to mergers and acquisitions.
Why Is Teladoc (TDOC) Down 12.8% Since Last Earnings Report?
by Zacks Equity Research
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SOC Telemed (TLMD) Aids Virtual Service Expansion of SCP Health
by Sapna Bagaria
SOC Telemed (TLMD) offers its cloud-based Telemed IQ platform to expedite SCP Health's virtual care expansion.
Will Teladoc (TDOC) Feel the Heat From SOC Telemed's Expansion?
by Zacks Equity Research
SOC Telemed's fund-raising program through investors for the second consecutive year to expand its operations might intensify competition for Teladoc Health (TDOC).
Will Teladoc's (TDOC) New Service Seize the Mental Health Space?
by Zacks Equity Research
Teladoc Health (TDOC) rolls out a complete mental care offering to tap the growing market for behavioral health care.
Is Teladoc Health (TDOC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TDOC) Outperforming Other Medical Stocks This Year?
Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $156.99, marking a -0.87% move from the previous day.
Teladoc (TDOC) Q1 Earnings Beat, 2021 Revenue Guidance Up
by Zacks Equity Research
Teladoc's (TDOC) Q1 results reflect revenue increase, led by higher membership and visits, partly offset by flared-up expenses.
Teladoc (TDOC) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 122.81% and 0.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Offing for Teladoc Health's (TDOC) Earnings in Q1?
by Zacks Equity Research
Teladoc's (TDOC) Q1 results are likely to reflect higher revenues, partly offset by inflated expenses.
3 Great Growth Stocks to Buy Now at a Discount
by Benjamin Rains
All of these factors create a bullish outlook and might make some investors consider buying strong growth stocks that have yet to fully recover from mid-February's tech and growth selloff...
Teladoc (TDOC) Stock Moves -0.77%: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $181.42 in the latest trading session, marking a -0.77% move from the prior day.
MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth
by Urmimala Biswas
While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.
Will Vaccine Under the Lens Aid Teladoc's (TDOC) Prospects?
by Zacks Equity Research
Teladoc Health (TDOC) is likely to gain as the J&J-AstraZeneca vaccine comes under the microscope. This will likely slacken the vaccination drive, causing investors to shift to at-home stocks.
Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $181.26, moving -0.58% from the previous trading session.
Here's Why You Should Retain Cigna (CI) in Your Portfolio
by Zacks Equity Research
Cigna (CI) is set to benefit from growing revenues, well-performing growth platforms and robust capital position.
The Zacks Analyst Blog Highlights: Facebook, Adobe, Novo Nordisk, PetroChina and Teladoc Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Adobe, Novo Nordisk, PetroChina and Teladoc Health
Teladoc (TDOC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $182.79, moving +0.57% from the previous trading session.
Top Analyst Reports for Facebook, Adobe & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Adobe (ADBE), and Novo Nordisk (NVO).
Teladoc (TDOC) Down 19.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Humana (HUM) Extends Ties for Automating Prior Authorizations
by Zacks Equity Research
Humana (HUM) expands partnership with Epic in a bid to offer electronic prior authorizations, member insights and other capabilities for patients and providers.
3 Highly-Ranked Non-Tech Stocks to Buy Now
by Benjamin Rains
Investors might want to consider buying a few stocks outside of the tech space right now, as the Nasdaq's massive run slows and some funds are transferred to cyclical sectors and the non-tech trade...